Estimates used to calculate effect of thrombophilia testing in individuals with a family history of VTE
| Thrombophilia defect in the family . | RR for first VTE, positive vs negative (95% CI) . | Treatment effect for VTE occurrence, RR (95% CI)∗ . | Treatment effect major bleeding, RR (95% CI)∗ . |
|---|---|---|---|
| FVL (FVL) | 2.71 (2.06-3.56) | 0.54 (0.32-0.91) | 2.09 (1.33-3.27) |
| Prothrombin (PT) mutation | 2.35 (1.46-3.78) | ||
| Antithrombin (AT) deficiency | 12.17 (5.45-27.17) | ||
| Protein C (PC) deficiency | 7.47 (2.81-19.81) | ||
| Protein S (PS) deficiency | 5.98 (2.45-14.57) |
| Thrombophilia defect in the family . | RR for first VTE, positive vs negative (95% CI) . | Treatment effect for VTE occurrence, RR (95% CI)∗ . | Treatment effect major bleeding, RR (95% CI)∗ . |
|---|---|---|---|
| FVL (FVL) | 2.71 (2.06-3.56) | 0.54 (0.32-0.91) | 2.09 (1.33-3.27) |
| Prothrombin (PT) mutation | 2.35 (1.46-3.78) | ||
| Antithrombin (AT) deficiency | 12.17 (5.45-27.17) | ||
| Protein C (PC) deficiency | 7.47 (2.81-19.81) | ||
| Protein S (PS) deficiency | 5.98 (2.45-14.57) |
Estimates taken from ASH Medical Prophylaxis guideline-medical outpatients with minor provoking risk factors for VTE.